CASiGEN Pharma created in Hong Kong to bring new potential diabetes treatments to global market

USA-based Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) have announced the creation of CASiGEN Pharma, with the aim of bringing new treatments for diabetes and other metabolic disorders to the global market.

CASiGEN received a world-wide exclusive license from GIBH that gives it access to new drug candidates addressing unmet medical needs in this field. CASiGEN is currently seeking investors to advance development of selected orally available small molecules targeting the ERR-alpha receptor as a potential diabetes treatment. The company will apply to join the Hong Kong Science & Technology Parks (HKSTP), a world class research park based in Hong Kong and within the Guangzhou region.

Commenting about the license agreement, Duanqing Pei, director general at GIBH, said: "The license agreement with CASiGEN Pharma constitutes an important milestone for GIBH as it takes a key research project to the global market in collaboration with an international team of pharma and biotech people from the United States and Europe."